These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33368776)

  • 1. Multimodal MRI Response to Fingolimod in Multiple Sclerosis: A Nonrandomized, Single Arm, Observational Study.
    Bernitsas E; Kopinsky H; Lichtman-Mikol S; Razmjou S; Santiago-Martinez C; Yarraguntla K; Bao F
    J Neuroimaging; 2021 Mar; 31(2):379-387. PubMed ID: 33368776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study.
    Saraste M; Bezukladova S; Sucksdorff M; Saunavaara V; Rissanen E; Matilainen M; Airas L
    Mult Scler Relat Disord; 2021 Feb; 48():102690. PubMed ID: 33352357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
    Preziosa P; Storelli L; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study.
    Zivadinov R; Hagemeier J; Bergsland N; Tavazzi E; Weinstock-Guttman B
    Eur J Neurol; 2018 Mar; 25(3):584-e36. PubMed ID: 29316038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: Magnetisation transfer, water diffusion and g-ratio.
    York EN; Meijboom R; Thrippleton MJ; Bastin ME; Kampaite A; White N; Chandran S; Waldman AD;
    Neuroimage Clin; 2022; 36():103228. PubMed ID: 36265199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments.
    Gurevich M; Waknin R; Stone E; Achiron A
    CNS Neurosci Ther; 2018 May; 24(5):412-419. PubMed ID: 29316271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.
    Alshehri A; Al-Iedani O; Koussis N; Khormi I; Lea R; Lechner-Scott J; Ramadan S
    Neuroradiol J; 2023 Aug; 36(4):388-396. PubMed ID: 36395524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
    Zivadinov R; Bergsland N; Hagemeier J; Carl E; Kolb H; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 May; 388():175-181. PubMed ID: 29627017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging.
    Shi Z; Pan Y; Yan Z; Ding S; Hu H; Wei Y; Luo D; Xu Y; Zhu Q; Li Y
    Mult Scler Relat Disord; 2023 Mar; 71():104572. PubMed ID: 36821979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability in progressive MS is associated with T2 lesion changes.
    Ammitzbøll C; Dyrby TB; Lyksborg M; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Garde E; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2018 Feb; 20():73-77. PubMed ID: 29324249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.
    de Kouchkovsky I; Fieremans E; Fleysher L; Herbert J; Grossman RI; Inglese M
    J Neurol; 2016 Jun; 263(6):1146-55. PubMed ID: 27094571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
    Filippi M; Pagani E; Turrini R; Bartezaghi M; Brescia Morra V; Borriello G; Torri Clerici V; Mirabella M; Pasquali L; Patti F; Totaro R; Gallo P; Rocca MA;
    J Neurol; 2024 Sep; 271(9):6181-6196. PubMed ID: 39073436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
    Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion tensor imaging in early relapsing-remitting multiple sclerosis.
    Griffin CM; Chard DT; Ciccarelli O; Kapoor B; Barker GJ; Thompson AI; Miller DH
    Mult Scler; 2001 Oct; 7(5):290-7. PubMed ID: 11724444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study.
    Klistorner A; Wang C; Yiannikas C; Parratt J; Dwyer M; Barton J; Graham SL; You Y; Liu S; Barnett MH
    Neuroimage Clin; 2018; 17():1028-1035. PubMed ID: 29387524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadolinium-Enhancing Lesions Lead to Decreases in White Matter Tract Fractional Anisotropy in Multiple Sclerosis.
    Chiang GC; Pinto S; Comunale JP; Gauthier SA
    J Neuroimaging; 2016 May; 26(3):289-95. PubMed ID: 26458494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis.
    Davies GR; Altmann DR; Hadjiprocopis A; Rashid W; Chard DT; Griffin CM; Tofts PS; Barker GJ; Kapoor R; Thompson AJ; Miller DH
    J Neurol; 2005 Sep; 252(9):1037-44. PubMed ID: 15834645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.